logo
Share SHARE
FONT-SIZE Plus   Neg

Reports: Amylin Seeks Buyers

Amylin Pharmaceuticals Inc. (AMLN), which rejected a $3.5 billion unsolicited takeover offer from Bristol-Myers Squibb Co. (BMY) in late March, has reportedly hired advisers to seek a sale of the company, reports said Sunday.

Early this month, activist investor Carl Icahn had filed a lawsuit against the diabetes drug maker to put pressure on it to pursue a deal to sell the company. Icahn owns about 9 percent of Amylin's shares.

Reports sugest that Credit Suisse Group AG and Goldman Sachs Group Inc. have been hired by the maker of Bydureon and Byetta as financial advisers on a potential sale. The company is said to have begun approaching potential buyers last week.

Several drugmakers, including France's Sanofi (SNY), could be mulling an offer for Amylin. Sanofi, though is discussing a bid internally, is said to be hesitant because Byetta will directly compete with the French drugmaker's experimental treatment lixisenatide.

AMLN closed on Friday at $22.92, down $0.15 or 0.66 percent, on a volume of 3.42 million shares.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Payments giant PayPal filed a lawsuit against music streaming company Pandora Media over alleged similarities in both companies' logos. The trademark infringement lawsuit was filed last week in U.S. District Court for the Southern District of New York, seeking legal costs and unspecified damages. PayPal also called for Pandora to cease use of its current blue "P" logo. Tiffany & Co. reported Wednesday higher profit in its first quarter, above market estimates. Net sales edged up, but missed market view amid lower comparable sales in all regions. Further, the company maintained its fiscal 2017 earnings view, but updated sales growth view on a constant exchange rate basis. In pre-market activity, Tiffany shares were losing 3.92 percent. Lowe's Co. reported Wednesday lower profit in its first quarter, reflecting a loss on extinguishment of debt, despite higher sales and comparable sales. Adjusted earnings per share and sales missed market estimates. Further, the company updated its fiscal 2017 earnings view to reflect the loss, and backed sales growth forecast. In pre-market activity, shares were declining 7.34 percent.
comments powered by Disqus
Follow RTT